* Arcturus Pharmaceutical Corp., of Woburn, Mass., received anotice of allowance for a U.S. patent covering technology for thetopical administration of physiologically active, irritating amines.

* PharmaGenics Inc., of Allendale, N.J., was issued U.S. patent No.5,362,623 for cell-based and cell-free assay systems to screen fordrugs that restore lost p53 tumor suppresser gene function.

* ARIAD Pharmaceuticals Inc., of Cambridge, Mass., said U.S.patent No. 5,352,660, titled "Method for assaying a substance thataffects a SH-2 phosphorylated ligand regulatory system," was issuedto Mount Sinai Hospital Corp., of Toronto. ARIAD has licensed allapplications of the technology, which covers drug discoveryinvolving intracellular signal transduction.

* Lexin Pharmaceutical Corp., of Horsham, Pa., said U.S. patent No.5,367,064, titled "Alpha-1 antichymotrypsin, analogues and methodsof production," was issued to the University of Pennsylvania inPhiladelphia. The patent is the third in a series licensed to Lexin forthe composition of its serine protease inhibitors, their methods ofproduction and DNA sequences.

* Receptagen Ltd., of Vancouver, Canada, has filed a U.S. patentapplication for the use of the coenzyme Q10 molecule and relatedcompositions for inhibiting apoptosis, or cell death.

(c) 1997 American Health Consultants. All rights reserved.